BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE: KG) today announced that it has initiated the Phase II clinical trial program evaluating the efficacy and safety of T-62, an oral tablet formulation, the Company’s investigational drug for the treatment of neuropathic pain.
